Physician profile
Patrick Thomas Schiller
NPI 1376004929
$2,395.92
in general payments reported to CMS, 2019-2025
22 companies · $1,487 in 2025
The $1,487 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2023: $206 · 2024: $598 · 2025: $1,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,291.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $419.69 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $235.43 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $225.13 | 2023-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $191.27 | 2024-2025 | Jynarque, Voyxact |
| Amgen INC. | $169.84 | 2024-2025 | Krystexxa, Tavneos |
| Lilly USA, LLC | $162.25 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $154.81 | 2023-2025 | Benlysta, Shingrix, Arexvy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $95.61 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.25 | 2024-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $73.92 | 2024 | Acthar, Terlivaz |
| Fresenius USA Marketing, INC. | $72.47 | 2024-2025 | Velphoro, Velphoro |
| Nxstage Medical, INC. | $69.92 | 2023 | Nxstage System One, Nxstage Cartridge Express |
| Bayer Healthcare Pharmaceuticals INC. | $69.43 | 2024-2025 | |
| Ardelyx, INC. | $67.37 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $62.56 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $57.53 | 2025 | Vafseo |
| Vifor Pharma, INC. | $49.40 | 2024-2025 | Veltassa |
| Apellis Pharmaceuticals, INC. | $32.44 | 2025 | |
| Aurinia Pharma U.S., INC. | $29.91 | 2024 | Lupkynis |
| Scpharmaceuticals INC. | $24.58 | 2025 | |
| Novo Nordisk INC | $22.79 | 2025 | Ozempic |
| Ascendis Pharma Endocrinology INC | $22.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Schiller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.